• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Applied Genetic Technologies Corporation

    12/8/22 12:42:24 PM ET
    $AGTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGTC alert in real time by email
    SC 13D 1 p22-2577sc13d.htm APPLIED GENETIC TECHNOLOGIES CORPORATION

     

    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Applied Genetic Technologies Corporation

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    03820J100

    (CUSIP Number)
     
    Sven Krogius

    c/o TFG Asset Management UK LLP

    399 Park Avenue, 22nd Floor

    New York, NY 10022

    +1 212 359 7300

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    November 28, 2022

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

    (Page 1 of 12 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 2 of 12 Pages

     

    1

    NAME OF REPORTING PERSON

    Tetragon Financial Group Limited

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC, OO (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Guernsey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    -0-

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 3 of 12 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Tetragon Financial Management L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    -0-

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 4 of 12 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Patrick G. G. Dear

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    -0-

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 5 of 12 Pages

     

    1

    NAME OF REPORTING PERSON

    Reade E. Griffith

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    -0-

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 6 of 12 Pages

     

     

    Item 1. SECURITY AND ISSUER
       
      This statement on Schedule 13D (the “Schedule 13D”) relates to the Common Stock, $0.001 par value per share (the “Common Stock”), of Applied Genetic Technologies Corporation, a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 14193 NW 119th Terrace, Suite 10, Alachua, Florida, 32165.

     

    Item 2. IDENTITY AND BACKGROUND
       
    (a) This statement is filed by:

     

      (i) Tetragon Financial Group Limited, a Guernsey company (“Tetragon”), with respect to the shares of Common Stock directly owned by it;
         
      (ii) Tetragon Financial Management L.P., a limited partnership organized under the laws of the State of Delaware (“Tetragon Manager”), as registered investment manager of Tetragon, with respect to the shares of Common Stock directly owned by Tetragon;
         
      (iii) Patrick G. G. Dear (“Mr. Dear”), as principal of Tetragon Manager, with respect to the shares of Common Stock directly owned by Tetragon; and
         
      (iv) Reade E. Griffith (“Mr. Griffith”), as principal of Tetragon Manager, with respect to the shares of Common Stock directly owned by Tetragon.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
       
    (b) The address of the principal office of each of Tetragon, Mr. Dear and Mr. Griffith is c/o TFG Asset Management UK LLP, 4 Sloane Terrace, London SW1X 9DQ, United Kingdom. The address of the principal office of Tetragon Manager is 399 Park Avenue, 22nd Floor, New York, New York 10022.
       
    (c) The principal business of Tetragon is to invest in securities. The principal business of Tetragon Manager is the management of the affairs of Tetragon. The principal business of each of Messrs. Dear and Griffith is the management of investments in securities.

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 7 of 12 Pages

     

    (d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
       
    (e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
       
    (f) Tetragon is a company organized under the laws of Guernsey. Tetragon Manager is a Delaware limited partnership.  Messrs. Dear and Griffith are citizens of the United Kingdom.
       
      Schedule A attached hereto sets forth the information required by Instruction C of the instructions to Schedule 13D.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
       
      Funds for the purchase of the shares of Common Stock to which this Schedule 13D relates were derived from working capital of Tetragon and margin account borrowings made in the ordinary course of business.  In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account, which may exist from time to time.  Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the shares of Class A Common Stock reported herein. A total of $1,281,629.91 was paid to acquire the 3,451,342 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the consummation of the Tender Offer (as defined in Item 4).

     

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 8 of 12 Pages

    Item 4. PURPOSE OF TRANSACTION
       
      On the date of the event which requires the filing of this Schedule 13D, each of the Reporting Persons may have been deemed to be the beneficial owner of more than five percent of the shares of Common Stock. Immediately prior to the consummation of the Tender Offer (as defined below), the Reporting Persons may have been deemed to beneficially own 3,451,342 shares of Common Stock.
       

      The Reporting Persons acquired the shares of Common Stock to which this Schedule 13D relates, pursuant to investment strategies, including merger arbitrage and event driven strategies, for investment purposes in the ordinary course of business, and not with the purpose nor with the effect of changing or influencing the control or management of the Issuer. However, the Reporting Persons may not be eligible to report on a Schedule 13G under the position taken by the SEC in the “Faith Colish” No-Action Letter and accordingly have determined to file on Schedule 13D. See Faith Colish (No-Act., Available March 24, 1980). On October 24, 2022, the Issuer filed a Current Report on Form 8-K disclosing it entered into an Agreement and Plan of Merger and Reorganization dated as of October 23, 2022 (the “Merger Agreement”) with Alliance Holdco Limited, a private limited company organized under the laws of England and Wales (the “Parent”), and Alliance Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (the “Purchaser”). The Merger Agreement provides for the acquisition of the Company by the Parent through a tender offer (the “Tender Offer”) by the Purchaser for all of the Company’s outstanding shares of Common Stock for: (1) $0.34 per share of Common Stock and (2) one contingent value right (each a “CVR”) per share of Common Stock representing the right to receive potential milestone payments pursuant to and subject to the terms of the CVR Agreement, as such amount may be increased in accordance with the terms of the Merger Agreement. On November 30, 2022, the Purchaser irrevocably accepted for payment all shares of Common Stock, including those tendered by the Reporting Persons, that were validly tendered, and not properly withdrawn, pursuant to the Tender Offer.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons.  

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 9 of 12 Pages

     

    (b)

    See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

     

    As disclosed in Item 4, on the date of the event which requires the filing of this Schedule 13D, each of the Reporting Persons may have been deemed to be the beneficial owner of more than five percent of the shares of Common Stock.

       
    (c) The transactions in the shares of Common Stock within the past sixty days by Tetragon, which were all in the open market, are set forth in Schedule B, and are incorporated herein by reference. The other Reporting Persons did not enter into any transactions in the shares of Common Stock within the past sixty days.
       
    (d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, such shares of Common Stock.
       
    (e) Not applicable.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
      Other than the Joint Filing Agreement attached as Exhibit 99.1 hereto, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS
       
    Exhibit 99.1: Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Act.

     

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 10 of 12 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: December 8, 2022

     

    TETRAGON FINANCIAL GROUP LIMITED
         
         
    By: /s/ Reade E. Griffith  
    Name: Reade E. Griffith  
    Title: Authorized Signatory  
         
         
    TETRAGON FINANCIAL MANAGEMENT L.P.
         
         
    By: /s/ Reade E. Griffith  
    Name: Reade E. Griffith  
    Title: Authorized Signatory  
         
         
    /s/ Patrick G.G. Dear  
    PATRICK G.G. DEAR  
         
         
    /s/ Reade E. Griffith  
    READE E. GRIFFITH  

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 11 of 12 Pages

    Schedule A

    GENERAL PARTNERS, CONTROL PERSONS, DIRECTORS AND EXECUTIVE OFFICERS OF CERTAIN REPORTING PERSONS

    The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of the applicable Reporting Persons (the “Instruction C Persons”). To the best of the Reporting Persons’ knowledge, (i) none of the Instruction C Persons during the last five years has been convicted in a criminal proceeding (excluding traffic violations or other similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws and (ii) none of the Instruction C Persons owns any shares of Common Stock or is party to any contract or agreement as would require disclosure in this Schedule 13D, except to the extent such Instruction C Person is a Reporting Person in which case such Instruction C Person’s beneficial ownership is as set forth in Item 5 of the Schedule 13D.

    REPORTING PERSON: Tetragon Financial Group Limited (“Tetragon”)

    Mr. Griffith, a Reporting Person, directly and through voting agreements, controls the voting shares of Tetragon.

    REPORTING PERSON: Tetragon Financial Management L.P. (“Tetragon Manager”)

    Tetragon Financial Management GP LLC (“TFMGP”) serves as the general partner of Tetragon Manager. Its business address is c/o National Corporate Research, Ltd., 615 South DuPont Highway, County of Kent, Dover, Delaware 19901. Its principal occupation is serving as the general partner of Tetragon Manager. TFMGP is a Delaware limited liability company.

    Polygon Credit Holdings Ltd. (“PCH”) serves as the sole member of TFMGP. Its business address is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104. Its principal occupation is serving as the sole member of TFMGP. PCH is a Cayman Islands company.

    REG Holdco II Ltd (“REG”) and Mr. Griffith, a Reporting Person, directly and indirectly, control the majority of the shares of PCH. REG’s business address is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104. Its principal occupation includes the management of the affairs of PCH. REG is a Cayman Islands company.

    Mr. Griffith, a Reporting Person, directly controls the voting shares of REG.

     

    CUSIP No. 03820J100

    SCHEDULE 13D

    Page 12 of 12 Pages

    Schedule B

    This Schedule sets forth information with respect to each purchase and sale of shares of Common Stock which were effectuated by Tetragon within the past sixty days. Unless otherwise noted, all transactions were effectuated in the open market through a broker. The price reported in the column Price Per Share ($) is a weighted average price if a price range is indicated in the column Price Range ($). These shares of Common Stock were purchased/sold in multiple transactions at prices between the price ranges below. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price.

     

    Trade Date Shares Purchased (Sold) Price Per Share ($)* Price Range ($)*
           
    11/23/2022 818,221 0.3679 0.3651 – 0.37
    11/25/2022 1,881,487 0.371 0.3655 – 0.375
    11/28/2022 739,688 0.3748 0.37 – 0.375
    11/29/2022 4,785 0.3749 0.37 – 0.375
    11/30/2022 7,161 0.375 0.3749 – 0.375
    11/30/2022 (3,451,342) 0.34**  
           
           
           
           
           
           

    *       Excluding commissions.
    **     Tender in the Tender Offer. 

    Get the next $AGTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AGTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

      Leading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothelial dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.c

      6/9/22 8:00:00 AM ET
      $AGTC
      $OCUL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the appointment of James Robinson, President and Chief Executive Officer (CEO) of Urovant Sciences, to its Board of Directors. "We are honored to have Jim join our Board of Directors, where his exemplary track record of execution as an executive at leading biotech and pharma companies will b

      12/6/21 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

      With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC's preclinical pipeline GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer. "A gene

      11/16/21 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today the successful completion of the previously announced tender offer (the "Offer") to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) ("Syncona"). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled t

      12/1/22 7:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) ("Syncona") has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones. The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022. The tender offer was previously scheduled to exp

      11/29/22 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • *FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specified milestones. We urge you to tender your shares in the offer.In order to tender, please contact your bank or broker, or follow the instructions that you previously received by mail or email from

      11/28/22 8:30:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Financials

    Live finance-specific insights

    See more
    • Syncona to Acquire Applied Genetic Technologies Corporation

      Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC's closing stock price on October 21, 2022 AGTC's Board has examined all alternative options for the future of AGTC and believes this transaction clearly delivers the best value for shareholders Given the state of equity and other funding markets, AGTC sees significant challenges in funding ongoing operations beyond 2022 Syncona and AGTC to host conference call on October 24, 2022 at 7:30 a.m. ET

      10/23/22 10:05:16 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

      – 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited ret

      5/16/22 4:01:00 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

      -Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced financial results for the quarter ended December 31, 2021. "We enter 2022 with significant momentum from the recent buildout of our management team

      2/14/22 7:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Robinson James A. Jr.

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:23:47 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Vanlent Anne

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:23:04 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Rosen James closing all direct ownership in the company (for withholding tax)

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:22:27 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG initiated coverage on Applied Genetic with a new price target

      BTIG initiated coverage of Applied Genetic with a rating of Buy and set a new price target of $11.00

      6/15/21 6:43:59 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel Nicolaus initiated coverage on Applied Genetic Technologies with a new price target

      Stifel Nicolaus initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

      3/8/21 8:22:11 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Applied Genetic Technologies with a new price target

      Stifel initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

      3/2/21 6:25:42 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Applied Genetic Technologies Corporation

      15-12G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/12/22 8:33:58 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Applied Genetic Technologies Corporation

      EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/7/22 12:15:06 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Applied Genetic Technologies Corporation

      EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/7/22 12:15:13 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Applied Genetic Technologies Corporation (Amendment)

      SC 13G/A - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      2/14/23 1:22:16 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Applied Genetic Technologies Corporation

      SC 13D - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      12/8/22 12:42:24 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Applied Genetic Technologies Corporation

      SC 13G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      11/4/22 4:24:20 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care